{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:59:20Z","timestamp":1788904760369,"version":"build-2803163510"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["APP 1123988"],"award-info":[{"award-number":["APP 1123988"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"APP","award":["2026490"],"award-info":[{"award-number":["2026490"]}]},{"name":"APP","award":["APP1138581"],"award-info":[{"award-number":["APP1138581"]}]},{"name":"APP","award":["APP149990"],"award-info":[{"award-number":["APP149990"]}]},{"name":"APP","award":["APP1145977"],"award-info":[{"award-number":["APP1145977"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>An effective therapeutic strategy for hepatis B virus (HBV) cure remains an urgent unmet need. We aimed to define the incidence, kinetics, and predictors of hepatitis B surface antigen (HBsAg) loss in people with HIV and HBV (PWH-HBV) following HBV-active antiretroviral therapy (ART) in PWH-HBV in Asia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>97 PWH-HBV commencing HBV-active ART were recruited prospectively in Thailand (n = 94) and Malaysia (n = 3), then followed for 24 months. Time to HBV serology change was calculated. Univariate associations between baseline characteristics and HBsAg loss were examined using the Mann-Whitney or chi-square tests. Multivariable analysis was undertaken using Cox regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-one individuals (22%) lost HBsAg during follow-up (11.7 per 100 person-years), 14 of whom gained anti-HBs. Twenty-two of 61 (36.1%) individuals who were hepatitis B \u201ce\u201d antigen (HBeAg) positive at baseline lost HBeAg over the study, 15 of whom gained anti-HBe. Most individuals lost HBsAg and HBeAg by the month 12 study visit (81% and 63.6%, respectively), with median times of 5.8 and 12.0 months to HBsAg and HBeAg loss, respectively. Univariate analysis showed baseline characteristics associated with HBsAg loss were higher alanine aminotransferase (ALT; P = .005), tenofovir alafenamide (TAF)\u2013containing ART regimen (P = .025), younger age (P = .040), lower liver stiffness (P = .010), and quantitative HBsAg &amp;lt; log10 2.0\u2005IU\/mL (P = .001). All 5 factors remained significant in a Cox regression analysis that adjusted for baseline CD4 count.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>High HBsAg loss rates occur in PWH and HBV early after commencing ART. Our study suggests that TAF-containing ART regimens may be preferable as first-line therapy in HIV-HBV coinfection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf281","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T07:42:47Z","timestamp":1748504567000},"page":"e176-e184","source":"Crossref","is-referenced-by-count":8,"title":["Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)\u2013Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6322-3197","authenticated-orcid":false,"given":"Jennifer","family":"Audsley","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3222-9611","authenticated-orcid":false,"given":"Anchalee","family":"Avihingsanon","sequence":"additional","affiliation":[{"name":"HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS and Infectious Diseases Research Centre (AIDSID), and Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4976-2562","authenticated-orcid":false,"given":"Rosalind","family":"Edwards","sequence":"additional","affiliation":[{"name":"Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Jackson","sequence":"additional","affiliation":[{"name":"Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Warner","sequence":"additional","affiliation":[{"name":"Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Maslac","sequence":"additional","affiliation":[{"name":"Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A","family":"Revill","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity , Melbourne ,","place":["Australia"]},{"name":"Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7869-3908","authenticated-orcid":false,"given":"Hay Mar Su","family":"Lwin","sequence":"additional","affiliation":[{"name":"HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS and Infectious Diseases Research Centre (AIDSID), and Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9511-370X","authenticated-orcid":false,"given":"Sivaporn","family":"Gatechompol","sequence":"additional","affiliation":[{"name":"HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS and Infectious Diseases Research Centre (AIDSID), and Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagalingeswaran","family":"Kumarasamy","sequence":"additional","affiliation":[{"name":"Infectious Diseases Medical Centre, Voluntary Health Services Hospital , Chennai ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Spelman","sequence":"additional","affiliation":[{"name":"Public Health, Burnet Institute , Melbourne ,","place":["Australia"]},{"name":"Department of Medicine, University of Adelaide , Adelaide ,","place":["Australia"]},{"name":"Department of Clinical Neuroscience, Karolinska Institute , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iskandar","family":"Azwa","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Department of Medicine, Faculty of Medicine, Universiti Malaya , Kuala Lumpur ,","place":["Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeeba","family":"Kamarulzaman","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Department of Medicine, Faculty of Medicine, Universiti Malaya , Kuala Lumpur ,","place":["Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon R","family":"Lewin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity , Melbourne ,","place":["Australia"]},{"name":"Victorian Infectious Diseases Service, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity , Melbourne ,","place":["Australia"]},{"name":"Department of Infectious Diseases, Alfred Hospital and Monash University , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Sasadeusz","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity , Melbourne ,","place":["Australia"]},{"name":"Victorian Infectious Diseases Service, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity , Melbourne ,","place":["Australia"]},{"name":"Department of Infectious Diseases, Alfred Hospital and Monash University , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,31]]},"reference":[{"key":"2026020904071236200_ciaf281-B1","author":"World Health Organization"},{"key":"2026020904071236200_ciaf281-B2","volume-title":"Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016\u20132021: actions for impact","author":"World Health Organization","year":"2021"},{"key":"2026020904071236200_ciaf281-B3","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/jvh.13217","article-title":"Prevalence and burden of HBV co-infection among people living with HIV: a global systematic review and meta-analysis","volume":"27","author":"Platt","year":"2020","journal-title":"J Viral Hepat"},{"key":"2026020904071236200_ciaf281-B4","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/QAI.0b013e3182a60f7d","article-title":"HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes","volume":"64","author":"Hamers","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026020904071236200_ciaf281-B5","doi-asserted-by":"crossref","first-page":"e61297","DOI":"10.1371\/journal.pone.0061297","article-title":"Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals","volume":"8","author":"Matthews","year":"2013","journal-title":"PLoS One"},{"key":"2026020904071236200_ciaf281-B6","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.gastro.2012.05.037","article-title":"Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-na\u00efve patients with chronic hepatitis B","volume":"143","author":"Lok","year":"2012","journal-title":"Gastroenterology"},{"key":"2026020904071236200_ciaf281-B7","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1086\/513296","article-title":"The enigma of concurrent hepatitis B surface antigen (HBsAg) and antibodies to HBsAg","volume":"44","author":"Gerlich","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2026020904071236200_ciaf281-B8","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1086\/513200","article-title":"Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection","volume":"44","author":"Zhang","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2026020904071236200_ciaf281-B9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jhep.2021.07.031","article-title":"Role of anti-HBs in functional cure of HBeAg+ chronic hepatitis B patients infected with HBV genotype A","volume":"76","author":"Xu","year":"2022","journal-title":"J Hepatol"},{"key":"2026020904071236200_ciaf281-B10","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12072-019-09953-4","article-title":"Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection","volume":"13","author":"Huang","year":"2019","journal-title":"Hepatol Int"},{"key":"2026020904071236200_ciaf281-B11","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/QAI.0000000000002386","article-title":"Long-term TDF-inclusive ART and progressive rates of HBsAg loss in HIV-HBV coinfection-lessons for functional HBV cure?","volume":"84","author":"Audsley","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026020904071236200_ciaf281-B12","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1097\/QAD.0000000000000795","article-title":"Rates and determinants of hepatitis B \u2018e\u2019 antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus","volume":"29","author":"Boyd","year":"2015","journal-title":"AIDS"},{"key":"2026020904071236200_ciaf281-B13","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/jgh.13156","article-title":"Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from sub-Saharan Africa","volume":"31","author":"Boyd","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"2026020904071236200_ciaf281-B14","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.3390\/v13071341","article-title":"Functional cure of hepatitis B virus infection in individuals with HIV-coinfection: a literature review","volume":"13","author":"Boyd","year":"2021","journal-title":"Viruses"},{"key":"2026020904071236200_ciaf281-B15","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/QAD.0b013e328352224d","article-title":"Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients","volume":"26","author":"Maylin","year":"2012","journal-title":"AIDS"},{"key":"2026020904071236200_ciaf281-B16","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1093\/infdis\/jiaa662","article-title":"Impact of immune reconstitution-induced hepatic flare on hepatitis B surface antigen loss in hepatitis B virus\/human immunodeficiency virus-1 coinfected patients","volume":"223","author":"Yoshikawa","year":"2021","journal-title":"J Infect Dis"},{"key":"2026020904071236200_ciaf281-B17","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/jvh.12175","article-title":"Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-\/HBV-coinfected patients","volume":"21","author":"Strassl","year":"2014","journal-title":"J Viral Hepat"},{"key":"2026020904071236200_ciaf281-B18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","article-title":"Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis","volume":"156","author":"Yeo","year":"2019","journal-title":"Gastroenterology"},{"key":"2026020904071236200_ciaf281-B19","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/hep.510290447","article-title":"Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men","volume":"29","author":"Colin","year":"1999","journal-title":"Hepatology"},{"key":"2026020904071236200_ciaf281-B20","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1002\/hep.22931","article-title":"Indications for therapy in hepatitis B","volume":"49","author":"Degertekin","year":"2009","journal-title":"Hepatology"},{"key":"2026020904071236200_ciaf281-B21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1161\/01.ATV.0000148324.63685.6a","article-title":"Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome","volume":"25","author":"Kerner","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026020904071236200_ciaf281-B22","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.tox.2007.11.021","article-title":"The current state of serum biomarkers of hepatotoxicity","volume":"245","author":"Ozer","year":"2008","journal-title":"Toxicology"},{"key":"2026020904071236200_ciaf281-B23","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.atherosclerosis.2005.11.036","article-title":"Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome","volume":"189","author":"Yamada","year":"2006","journal-title":"Atherosclerosis"},{"key":"2026020904071236200_ciaf281-B24","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(02)11913-1","article-title":"HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)","volume":"360","author":"Thio","year":"2002","journal-title":"Lancet"},{"key":"2026020904071236200_ciaf281-B25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1742-6405-9-6","article-title":"Assessment of HBV flare in a randomized clinical trial in HIV\/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand","volume":"9","author":"Avihingsanon","year":"2012","journal-title":"AIDS Res Ther"},{"key":"2026020904071236200_ciaf281-B26","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1086\/597276","article-title":"Immunopathogenesis of hepatic flare in HIV\/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy","volume":"199","author":"Crane","year":"2009","journal-title":"J Infect Dis"},{"key":"2026020904071236200_ciaf281-B27","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3748\/wjg.v27.i7.641","article-title":"Effect of liver inflammation on accuracy of FibroScan device in assessing liver fibrosis stage in patients with chronic hepatitis B virus infection","volume":"27","author":"Huang","year":"2021","journal-title":"World J Gastroenterol"},{"key":"2026020904071236200_ciaf281-B28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2893.2010.01275.x","article-title":"Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV\/HBV-coinfected patients","volume":"18","author":"Miailhes","year":"2011","journal-title":"J Viral Hepat"},{"key":"2026020904071236200_ciaf281-B29","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/hep.30825","article-title":"Evaluating noninvasive markers to identify advanced fibrosis by liver biopsy in HBV\/HIV co-infected adults","volume":"71","author":"Sterling","year":"2020","journal-title":"Hepatology"},{"key":"2026020904071236200_ciaf281-B30","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1517\/17425255.2.3.459","article-title":"Tenofovir disoproxil fumarate for the treatment of HIV infection","volume":"2","author":"Pham","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026020904071236200_ciaf281-B31","volume-title":"Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection","author":"World Health Organization","year":"2015"},{"key":"2026020904071236200_ciaf281-B32","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.2147\/DDDT.S126742","article-title":"Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy","volume":"11","author":"Ogawa","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"2026020904071236200_ciaf281-B33","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/QAI.0000000000001069","article-title":"Brief report: efficacy and safety of switching to a single-tablet regimen of elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide in HIV-1\/hepatitis B-coinfected adults","volume":"73","author":"Gallant","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026020904071236200_ciaf281-B34","doi-asserted-by":"crossref","first-page":"13505","DOI":"10.7196\/SAMJ.2022.v112i2.16188","article-title":"Tenofovir alafenamide: an initial experience at Groote Schuur Hospital, Cape Town, South Africa","volume":"112","author":"Geragotellis","year":"2022","journal-title":"S Afr Med J"},{"key":"2026020904071236200_ciaf281-B35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/QAI.0000000000002589","article-title":"Efficacy and safety of elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide as maintenance treatment in HIV\/HBV-coinfected patients","volume":"86","author":"Huang","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026020904071236200_ciaf281-B36","doi-asserted-by":"crossref","first-page":"e0512522","DOI":"10.1128\/spectrum.05125-22","article-title":"Week 96 results of switching from tenofovir disoproxil fumarate-based antiretroviral therapy to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide among HIV\/hepatitis B virus-coinfected patients","volume":"11","author":"Huang","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2026020904071236200_ciaf281-B37","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/QAI.0000000000003079","article-title":"Brief report: effect of antiretroviral switch from tenofovir disoproxil fumarate to tenofovir alafenamide on alanine aminotransferase, lipid profiles, and renal function in HIV\/HBV-coinfected individuals in a nationwide Canadian study","volume":"91","author":"Sarowar","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026020904071236200_ciaf281-B38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/QAI.0000000000002429","article-title":"Brief report: switching from TDF to TAF in HIV\/HBV-coinfected individuals with renal dysfunction\u2014a prospective cohort study","volume":"85","author":"Surial","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026020904071236200_ciaf281-B39","doi-asserted-by":"crossref","first-page":"486","DOI":"10.14309\/ajg.0000000000002468","article-title":"Long-term treatment with tenofovir alafenamide for chronic hepatitis B results in high rates of viral suppression and favorable renal and bone safety","volume":"119","author":"Chan","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026020904071236200_ciaf281-B40","doi-asserted-by":"crossref","first-page":"e640","DOI":"10.1016\/S2352-3018(23)00151-0","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial","volume":"10","author":"Avihingsanon","year":"2023","journal-title":"Lancet HIV"},{"key":"2026020904071236200_ciaf281-B41","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1097\/QAD.0000000000001080","article-title":"Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity","volume":"30","author":"Audsley","year":"2016","journal-title":"AIDS"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf281\/63408713\/ciaf281.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/1\/e176\/63408713\/ciaf281.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/1\/e176\/63408713\/ciaf281.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T09:07:25Z","timestamp":1770628045000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/1\/e176\/8154127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,5,31]]},"published-print":{"date-parts":[[2026,2,9]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf281","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,15]]},"published":{"date-parts":[[2025,5,31]]}}}